These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 37573615)
1. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure. Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615 [TBL] [Abstract][Full Text] [Related]
2. Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction. Schupp T; Bertsch T; Reinhardt M; Abel N; Schmitt A; Lau F; Abumayyaleh M; Akin M; Weiß C; Weidner K; Behnes M; Akin I Eur J Prev Cardiol; 2024 Aug; 31(11):1347-1360. PubMed ID: 38513366 [TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Martin N; Manoharan K; Davies C; Lumbers RT Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072 [TBL] [Abstract][Full Text] [Related]
4. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Tomasoni D; Pagnesi M; Colombo G; Chiarito M; Stolfo D; Baldetti L; Lombardi CM; Adamo M; Maggi G; Inciardi RM; Loiacono F; Maccallini M; Villaschi A; Gasparini G; Montella M; Contessi S; Cocianni D; Perotto M; Barone G; Merlo M; Cappelletti AM; Rosano G; Sinagra G; Pini D; Savarese G; Metra M Eur J Heart Fail; 2024 Feb; 26(2):327-337. PubMed ID: 37933210 [TBL] [Abstract][Full Text] [Related]
5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095 [TBL] [Abstract][Full Text] [Related]
6. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629 [TBL] [Abstract][Full Text] [Related]
7. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971 [TBL] [Abstract][Full Text] [Related]
9. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928 [TBL] [Abstract][Full Text] [Related]
10. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020. Karlström P; Pivodic A; Dahlström U; Fu M Clin Res Cardiol; 2024 Sep; 113(9):1355-1368. PubMed ID: 39186181 [TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712 [TBL] [Abstract][Full Text] [Related]
12. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570 [TBL] [Abstract][Full Text] [Related]
13. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study. Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J; Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622 [TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020. Ødegaard KM; Lirhus SS; Melberg HO; Hallén J; Halvorsen S ESC Heart Fail; 2023 Feb; 10(1):405-415. PubMed ID: 36266969 [TBL] [Abstract][Full Text] [Related]
16. "Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review. Sudani HA; Shah S; Lo KB; Essa H; Wattoo A; Angelim L; Brousas S; Whybrow-Huppatz I; Vellanki S; Sankaranarayanan R; Rangaswami J Curr Vasc Pharmacol; 2023; 21(2):106-110. PubMed ID: 36918781 [TBL] [Abstract][Full Text] [Related]
17. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001 [TBL] [Abstract][Full Text] [Related]
18. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
19. The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta-analysis. Leite M; Sampaio F; Saraiva FA; Diaz SO; Barros AS; Fontes-Carvalho R ESC Heart Fail; 2023 Jun; 10(3):1822-1834. PubMed ID: 36896801 [TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. Tromp J; Ouwerkerk W; van Veldhuisen DJ; Hillege HL; Richards AM; van der Meer P; Anand IS; Lam CSP; Voors AA JACC Heart Fail; 2022 Feb; 10(2):73-84. PubMed ID: 34895860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]